CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 120 enrolled
Drug / intervention
regadenosondrug
Likely dose
regadenoson 0.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00857792
NCT00857792N/ACompleted
CompareCT.gov

Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging

University of Chicago·interventional·Posted Mar 9, 2009·Updated May 11, 2016

In Brief

A clinical study evaluating regadenoson for Coronary Disease. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The investigators goals are: 1. to develop software for quantitative volumetric analysis of myocardial perfusion from MDCT images 2. to test its ability to accurately determine the presence, location, extend and severity of perfusion abnormalities in agreement with conventional diagnostic techniques (ICA and MPI) in patients with normal and abnormal coronary arteries and/or perfusion patterns 3. to test this approach in patients undergoing vasodilator stress tests with MDCT imaging in combination with the new vasodilator stress agent Regadenoson.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease
CountriesUnited States
CollaboratorsAstellas Pharma Inc

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 9, 2009
Enrollment StartMar 1, 2009
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.3 years ago

Interventions

regadenosondrug

Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).